TrialBritish journal of haematology2026

Mosunetuzumab is effective and well tolerated in older patients with relapsed/refractory follicular lymphoma: Subgroup analysis of a phase I/II study.

Swetha Kambhampati Thiruvengadam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.